Presenter: Alena Guggenheim, ND

Original Date: November 7, 2021

Fibromyalgia has historically and categorically been written off as "not autoimmune”. Emerging data indicates otherwise. This will likely have a profound impact on how we define and treat the disorder.

Presentation overview:

• Introduction: Historical perspective on diagnosis, proposed pathogenesis, epidemiology
• Currently biomedical approach to treatment including pharmaceutical management: antidepressants, SNRIs; SSRIs; Tricyclics; Anti-Seizure Medicines; muscle relaxers. Medications that are not intended for treatment including opioids
• Emerging data that supports autoimmunity as an underpinning of disease
• Passive transfer studies
• Small fiber neuropathy
• Possible treatment explanations/ modifications (including pharma interactions)
• Possible ramifications for patients
• Includes case study examples

0.5 Pharmacology and 1.0 General (Total 1.5 CEUs) approved by OBNM